Immune Responses to Allogeneic and Xenogeneic Implants of Collagen and Collagen Derivatives

DeLustro, Frank; Dasch, James R.; Keefe, Jeannine; Ellingsworth, Larry

doi:10.1097/00003086-199011000-00043

Cited by 205 publications

(122 citation statements)

References 0 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Twenty-four month central disc height 4.6% less than pre-operative one transient increase in antibody levels post-operatively; but over time antibody levels approximated the pre-operative level in all patients. The presence of antibody and transient changes are in line with those reported in the use of other protein-based products, e.g., collagen and serum albumin [26,27]. In all cases, including the present study, the presence of an antibody response has had no correlation with clinical outcome or response.…”

Section: Discussionsupporting

confidence: 89%

An injectable nucleus replacement as an adjunct to microdiscectomy: 2 year follow-up in a pilot clinical study

Berlemann¹,

Schwarzenbach²

2009

Eur Spine J

View full text Add to dashboard Cite

Literature indicates that loss of disc tissue from herniation and/or surgery can accelerate degeneration of the disc. The associated loss of disc height may correspond with recurrent back and/or leg pain. A novel hydrogel has been developed to replace lost nucleus pulposus and potentially restore normal disc biomechanics following herniation and surgery. A single-center, non-randomized, prospective feasibility study was undertaken to investigate the use of NuCore Ò Injectable Nucleus hydrogel (Spine Wave, Inc., Shelton, CT, USA) as a replacement for nuclear tissue lost to herniation and microdiscectomy. Fourteen patients were enrolled at the authors' hospital as the initial site in a worldwide multicenter pilot study. Subjects who were entered into the study suffered from radicular pain due to single-level herniated nucleus pulposus and were non-respondent to conservative therapy. Following a standard microdiscectomy procedure, the hydrogel material was injected into the nuclear void to replace what tissue had been lost to the herniation and surgery. Leg and back pain, function and disability scores were monitored pre-and post-operatively through 2 years. Neurologic and physical evaluations, blood and serum analyses, and radiographic evaluations of disc height and implant stability were also performed. Results showed significant improvement for leg and back pain, as well as function scores. No complications or device related adverse events were observed. MR controls confirmed stable position of the implants with no reherniations. Radiographic measurements indicated better maintenance of disc height compared to literature data on microdiscectomy alone. The NuCore Ò material appears to protect the disc from early collapse following microdiscectomy; and therefore, may have the potential to slow the degenerative cascade of the spinal segment over time.

show abstract

Section: Discussionsupporting

confidence: 89%

An injectable nucleus replacement as an adjunct to microdiscectomy: 2 year follow-up in a pilot clinical study

Berlemann¹,

Schwarzenbach²

2009

Eur Spine J

View full text Add to dashboard Cite

show abstract

“…Collagen from animal sources has previously been the preferred carrier material in animal experiments. However, problems remain with the use of animal-derived collagen, including the risk of antibody generation or disease transmission and lack of mechanical strength of the carrier collagen [3,8,10]. To overcome these problems, synthetic biodegradable polymers have recently been tested as a delivery vehicle for osteoinductive agents.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of interspinous process lumbar fusion with recombinant human bone morphogenetic protein-2 delivered with a synthetic polymer and β-tricalcium phosphate in a rabbit model

et al. 2011

View full text Add to dashboard Cite

Introduction As a powerful bone-inducing cytokine, rhBMP-2 has been used as a bone graft substitute in combination with animal-derived collagen to achieve interbody or posterolateral spinal fusion. Successful interspinous process fusion using rhBMP-2 in combination with synthetic carrier materials would offer a safe, minimally invasive spinal fusion option for the treatment of spinal disorders. The aims of the present study were to achieve interspinous process fusion by implanting rhBMP-2-retaining degradable material instead of bone grafting and to evaluate efficacy for vertebral stabilization. Materials and methods A polymer gel (200 mg), btricalcium phosphate powder (400 mg), and rhBMP-2 (0, 30, 60 or 120 lg) were mixed to generate a plastic implant, which was then placed during surgery to bridge the L5-6 interspinous processes of 58 rabbits. Control animals received implants either without rhBMP-2 or with autogenous bone chips from the iliac crest. L5-6 vertebrae were recovered 8 weeks postoperatively. Interspinous process fusion was evaluated by radiography, biomechanical bending test, intradiscal pressure (IDP) measurement, and histology. Results In bending tests, strength of fusion was significantly greater in BMP60 and BMP120 groups than in sham, BMP0, BMP30 or autogenous bone groups. IDP at L5-6 was significantly reduced in BMP60 and BMP120 groups compared to sham, BMP0, BMP30, and autograft groups. Histologically, coronal sections of the fusion mass showed a bone mass bridging both spinous processes. ConclusionSolid interspinous process fusion was achieved in rabbit models by 8 weeks after implanting the biodegradable bone-inducing material. These results suggest a potential new less-invasive option without bone grafting for the treatment of lumbar disorders.

show abstract

“…Fetal bovine serum (FBS), RPMI 1640 medium, Dulbecco's Modified Eagle Medium (DMEM), basic fibroblast growth factor (bFGF), transforming growth factor-β1 (TGF-β1), penicillin and streptomycin (Pen-Strep), Fungizone, nonessential amino acids (NEAA, consisting of 8.9 mg/l L-alanine, 13.21 mg/l L-asparagine, 13.3 mg/l L-aspartic acid, 14.7 mg/l L-glutamic acid, 7.5 mg/l glycine, 11.5 mg/l L-proline, 10.5 mg/l L serine), and trypsin were from Gibco (Carlsbad, CA). Ascorbic acid-2-phosphate, Histopaque-1077, insulin, and dexamethasone were from Sigma (St. Louis, MO).…”

Section: Methodsmentioning

confidence: 99%

“…Orthopedic surgeons would therefore benefit from the introduction of osteopromotive scaffolds that could be used to enhance migration and/or delivery of osteogenic cells and cytokines. These materials should combine essential characteristics including biocompatibility, porosity, and appropriate mechanical properties [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Silk based biomaterials to heal critical sized femur defects

Meinel

Betz

Fajardo

et al. 2006

Bone

218

179

View full text Add to dashboard Cite

Immune Responses to Allogeneic and Xenogeneic Implants of Collagen and Collagen Derivatives

Cited by 205 publications

References 0 publications

An injectable nucleus replacement as an adjunct to microdiscectomy: 2 year follow-up in a pilot clinical study

An injectable nucleus replacement as an adjunct to microdiscectomy: 2 year follow-up in a pilot clinical study

Efficacy of interspinous process lumbar fusion with recombinant human bone morphogenetic protein-2 delivered with a synthetic polymer and β-tricalcium phosphate in a rabbit model

Silk based biomaterials to heal critical sized femur defects

Contact Info

Product

Resources

About